U.S. markets close in 3 hours 43 minutes
  • S&P 500

    4,175.86
    +56.65 (+1.38%)
     
  • Dow 30

    33,950.02
    -142.94 (-0.42%)
     
  • Nasdaq

    12,160.49
    +344.17 (+2.91%)
     
  • Russell 2000

    1,997.07
    +36.25 (+1.85%)
     
  • Crude Oil

    76.66
    +0.25 (+0.33%)
     
  • Gold

    1,933.20
    -9.60 (-0.49%)
     
  • Silver

    23.67
    +0.06 (+0.24%)
     
  • EUR/USD

    1.0925
    -0.0068 (-0.62%)
     
  • 10-Yr Bond

    3.3670
    -0.0300 (-0.88%)
     
  • GBP/USD

    1.2260
    -0.0112 (-0.90%)
     
  • USD/JPY

    128.3620
    -0.5630 (-0.44%)
     
  • BTC-USD

    23,812.45
    +815.53 (+3.55%)
     
  • CMC Crypto 200

    544.03
    -1.28 (-0.24%)
     
  • FTSE 100

    7,820.16
    +59.05 (+0.76%)
     
  • Nikkei 225

    27,402.05
    +55.17 (+0.20%)
     

Nabriva's stock is up after sharing antibiotic news

Nabriva's stock is up after sharing antibiotic news

Shares of Nabriva Therapeutics Plc were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia. Nabriva plans to share more details from the open-label CF study in the first half of next year. The company's stock has tumbled 85.5% this year, while the broader S&P 500 is down 15.5%.